News

mlive11m
Battle of the weight loss blockbuster drugs: Zepbound beats Wegovy by nearly 50%
Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.
Endpoints News46m
Lil­ly says fur­ther head-to-head tri­al da­ta back Zep­bound over No­vo’s We­govy
New data shows Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in weight loss, with 65% vs 40% of patients achieving ...